Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus

• Conditions: Systemic Lupus Erythematosus; Lichen Planus

• Registration Number: NCT04356014
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.

Detailed Description

Context: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) is a rare phenomenon seldom reported in literature. To our knowledge no case has been described in subacute cutaneous lupus erythematosus (SCLE) so far. Pathogeny and etiologic origin are not clear: it could be no-specific cutaneous manifestation of SLE, verrucous chilblain lupus, lichen planus, discoid lupus erythematosus lesions, overlap syndrome or coexistence of both diseases.

Objective:

1. Determine clinical immunological and histopathological features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE

2. Describe the different therapeutics used and efficacy assessment Methods: Multicentric retrospective descriptive study reporting 14 patients with SLE or SCLE suffering from an acral livid erythematosus keratoderma, with clinical data regarding lupus erythematosus and acral keratoderma, immunological blood samples findings and histopathological results of keratoderma and livid erythema biopsies with direct immunofluorescence if performed. The treatments set down in order to heal are noted followed by efficacy assessment: total failure, partial remission, complete remission.

Study Timeline

• Status Verified: 2020-03
• Study Start: 2020-04-01
• Study First Submitted: 2020-04-16
• Study First Submitted QC: 2020-04-19
• Last Update Submitted: 2020-04-19
• Study First Posted: 2020-04-21
• Last Update Posted: 2020-04-21
• Primary Completion: 2020-11-30
• Study Completion: 2020-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine clinic immunologic features	1 day	Determine clinic immunologic features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE.
Determine clinic histopathologic features	1 day	Epidemiologic clinic immunologic histopathologic data

Secondary Outcome Measures

Name	Time	Method
Different therapeutics used	1 day	Describe the different therapeutics used. Report of the drug therapy used to heal acral keratoderma for each patient
Different therapeutics efficacy assessment	1 day	Efficacy assessment of the treatments: total failure, partial remission, complete remission

Trial Locations

Locations (1)

Uh Montpellier; 🇫🇷 Montpellier, France